2026-04-17T04:08:11Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4825502025-10-27T12:44:14Zcom_2072_98col_2072_378192

00925njm 22002777a 4500 dc Ricart, Marta author Bonacina, Erika author Garcia-Manau, Pablo author López, Monica author Caamiña Álvarez, Sara author Vives, Àngels author Lopez-Quesada, Eva author Maroto, Anna author de Mingo, Laura author Pintado, Elena author Ferrer Costa, Roser author Martin Gonzalez, Lourdes author Rodriguez-Zurita, Alicia author Garcia Cancela, Esperanza author Pallarols Badia, Mar author Pratcorona, Laia author Teixidor, Mireia author Orizales Lago, Carmen María author Ocaña, Vanesa author del Barco, Ester author Carreras Moratonas, Elena author Suy, Anna author Mendoza, Manel author 2024 Altres ajuts: acords transformatius de la UAB This study aims to evaluate the safety of discontinuing aspirin treatment at 24-28 weeks in women at high risk after first-trimester combined screening for preeclampsia (PE) and normal placental growth factor (PlGF) levels at 24-28 weeks of gestation. This is a post hoc analysis of the StopPRE trial, conducted at nine Spanish maternity hospitals from September 2019 to September 2021. In the StopPRE trial, all high-risk single pregnancies identified during first-trimester screening for PE were treated with 150 mg of daily aspirin. Out of 1604 eligible women with a soluble fms-like tyrosine kinase-1 to PlGF ratio (sFlt-1/PlGF) ≤38 at 24-28 weeks, 968 were randomly assigned in a 1:1 ratio to either continue aspirin until 36 weeks (control group) or discontinue it (intervention group). In this secondary analysis, only women with PlGF ≥100 pg/mL at 24-28 weeks were included. As in the StopPRE trial, the non-inferiority margin was set at a 1.9% difference in preterm PE incidence between the groups. Among the 13 983 screened pregnant women, 1984 (14.2%) were deemed high-risk for preterm PE, of which 397 (20.0%) were ineligible, 636 declined participation, and 32 were excluded. Ultimately, 919 women with PlGF >100 pg/mL were randomized and included in this analysis. Preterm PE occurred in 0.9% of the intervention group (4 out of 465) and 1.5% of the control group (7 out of 454), indicating non-inferiority of aspirin discontinuation. There were no significant differences between the groups in adverse pregnancy outcomes before 37 weeks, at <34 weeks, or ≥37 weeks. Minor antepartum hemorrhage incidence was significantly lower in the intervention group (absolute difference, −5.96; 95% CI, −10.10 to −1.82). Discontinuation of aspirin treatment at 24-28 weeks in women with PlGF levels ≥100 pg/mL was non-inferior to continuing until 36 weeks for preventing preterm PE. However, these findings should be interpreted with caution, as they originate from a subanalysis of the StopPRE trial. Aspirin PlGF Preeclampsia Salicylic acid Screening preeclampsia Placental growth factor at 24-28 weeks for aspirin discontinuation in pregnancies at high risk for preterm preeclampsia : Post hoc analysis of trial